Oppenheimer Initiates Coverage On Kyntra Bio with Outperform Rating, Announces Price Target of $35

Oppenheimer analyst Jay Olson initiates coverage on Kyntra Bio (NASDAQ:KYNB) with a Outperform rating and announces Price Target of $35.